1 tracked superinvestor hold GSK PLC (GSK.L), worth $118M combined, led by Joel Tillinghast. Smart money is accumulating GSK.L as of the latest 13F filings.
Current price
$1969.00
Superinvestors holding
1
tracked 13F / N-PORT funds
Combined value
$118M
disclosed long exposure
Tier-1 conviction
0
concentrated holders
Net this quarter
+1
1 buying · 0 selling
Smart money is net accumulating GSK.L: 1 funds added or opened versus 0 trimming. 1 opened a brand-new position.
GSK PLC (GSK.L) appears mainly in diversified and quant books here (1 funds, $118M combined) rather than in concentrated conviction portfolios — read the holders below with that in mind.
The largest position belongs to Joel Tillinghast at 0.5% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
This quarter 1 fund opened a brand-new position (Joel Tillinghast), with 0 adding and 0 trimming — a net accumulation signal.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| New buy | 0.5% | $118M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
Which superinvestors own GSK.L?
1 tracked funds hold GSK PLC (GSK.L), the largest being Joel Tillinghast (Fidelity Low-Priced Stock) at 0.5% of its 13F portfolio. 0 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling GSK.L?
In the most recent 13F quarter, 1 tracked fund added or opened GSK.L and 0 trimmed it, including 1 brand-new position.
How much GSK.L do tracked funds hold?
Combined disclosed long exposure to GSK.L across tracked superinvestors is $118M as of the Mar 2026 filings.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Mar 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.